PPCBNasdaqPharmaceutical PreparationsFiscal year ends June 30
Propanc Biopharma, Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 25, 2026
$0.32−0.03 (-7.31%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Propanc Biopharma has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Propanc Biopharma filed with the SEC
Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering
Material agreement · Executive or director change · Other events · EX-99.1 to Form 8-K
Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ
Material agreement · Executive or director change · Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K